Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 155

Similar articles for PubMed (Select 23209317)

1.

Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors.

Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A.

J Exp Med. 2012 Dec 17;209(13):2351-65. doi: 10.1084/jem.20120944. Epub 2012 Dec 3.

2.

CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer.

Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y.

J Immunol. 2006 Feb 1;176(3):1582-7.

3.

In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18.

Baxevanis CN, Gritzapis AD, Papamichail M.

J Immunol. 2003 Sep 15;171(6):2953-9.

4.
5.

Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.

Li T, Harada M, Tamada K, Abe K, Nomoto K.

Anticancer Res. 1997 Nov-Dec;17(6D):4259-68.

PMID:
9494518
6.

Tumor-induced suppression of interferon-gamma production and enhancement of interleukin-10 production by natural killer (NK) cells: paralleled to CD4+ T cells.

Wei H, Zheng X, Lou D, Zhang L, Zhang R, Sun R, Tian Z.

Mol Immunol. 2005 May;42(9):1023-31. Epub 2004 Nov 23.

PMID:
15829292
7.

Induction of natural killer cell-dependent antitumor immunity by the Autographa californica multiple nuclear polyhedrosis virus.

Kitajima M, Abe T, Miyano-Kurosaki N, Taniguchi M, Nakayama T, Takaku H.

Mol Ther. 2008 Feb;16(2):261-8. Epub 2007 Dec 4.

PMID:
18059370
8.

NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.

Salagianni M, Lekka E, Moustaki A, Iliopoulou EG, Baxevanis CN, Papamichail M, Perez SA.

J Immunol. 2011 Mar 15;186(6):3327-35. doi: 10.4049/jimmunol.1000652. Epub 2011 Feb 11.

9.
10.

Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.

Tanaka F, Hashimoto W, Okamura H, Robbins PD, Lotze MT, Tahara H.

Cancer Res. 2000 Sep 1;60(17):4838-44.

11.
12.

The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.

PMID:
16525645
13.
14.

The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent.

Smyth MJ, Taniguchi M, Street SE.

J Immunol. 2000 Sep 1;165(5):2665-70.

15.

NK and CD4 cells collaborate to protect against melanoma tumor formation in the brain.

Prins RM, Vo DD, Khan-Farooqi H, Yang MY, Soto H, Economou JS, Liau LM, Ribas A.

J Immunol. 2006 Dec 15;177(12):8448-55.

16.

Cellular mechanisms of interleukin-12-mediated neuroblastoma regression.

Redlinger RE Jr, Shimizu T, Remy T, Alber S, Watkins SC, Barksdale EM Jr.

J Pediatr Surg. 2003 Feb;38(2):199-204.

PMID:
12596103
18.

Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.

Hokland M, Kjaergaard J, Kuppen PJ, Nannmark U, Agger R, Hokland P, Basse P.

In Vivo. 1999 May-Jun;13(3):199-204.

PMID:
10459491
19.

Interleukin-18 in combination with IL-2 enhances natural killer cell activity without inducing large amounts of IFN-gamma in vivo.

Arai N, Akamatsu S, Arai S, Toshimori Y, Hanaya T, Tanimoto T, Ikeda M, Tomura M, Fujiwara H, Kurimoto M.

J Interferon Cytokine Res. 2000 Feb;20(2):217-24.

PMID:
10714558
20.

Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.

Xia D, Zheng S, Zhang W, He L, Wang Q, Pan J, Zhang L, Wang J, Cao X.

J Mol Med (Berl). 2003 Sep;81(9):585-96. Epub 2003 Aug 21.

PMID:
12937899
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk